Shared decision-making in gout treatment: a national study of rheumatology provider opinion and practice

Singh, Jasvinder A.; Richards, J. Steuart; Chang, Elizabeth; Toupin‐April, Karine; Barton, Jennifer L.

doi:10.1007/s10067-020-05421-9

Cited by 6 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study in the USA on rheumatologists’ views and practices related to SDM in gout treatment revealed that 70% of the rheumatologists reported to offer patients offering a choice whether or not to start ULT without a DA. 44 Our DA might support patients and physicians in this shared decision.…”

Section: Discussionmentioning

confidence: 92%

Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients

et al. 2022

View full text Add to dashboard Cite

AimShared decision-making improves patients’ experiences with care, satisfaction with management decisions and possibly health outcomes. This study describes the development of a decision aid (DA) that supports patients with gout and their physicians in a face-to-face clinical setting to (a) decide whether or not to (re)start urate-lowering therapy (ULT) and (b) agree on the preferred ULT.MethodsRecommendations of the International Patient Decision Aid Standards group guided the development. A steering group of experts in gout and health services research specified the scope. Nominal group technique meetings were organised in which patients ranked the importance of preidentified potential characteristics/attributes of ULT and discussed further needs regarding the DA. A literature search was conducted to collect evidence on gout outcomes with and without ULT. Subsequently, the DA prototype was designed and adjusted using feedback from the steering group and results of cognitive debriefing interviews among five gout patients.ResultsThe final DA consists of six pages. First, the DA clarifies the decision at stake and describes gout including its risk factors, the role of lifestyle and treatment of flares. Next, risk of future flares with and without ULT in relation to serum uric acid levels is described and visualised. Relevant attributes of ULT are presented in an option grid distinguishing first-line and second-line ULT. Finally, patients’ believes and preferences are explicitly addressed before making the shared decision.ConclusionThis study provides initial support for usability of a DA for gout patients eligible for starting ULT.

show abstract

Section: Discussionmentioning

confidence: 92%

Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…31 In addition to addressing bone-related problems, rheumatologists are progressively inclined to engage in discussions pertaining to aspects beyond the direct pharmacological management of joint ailments, including patient quality of life and education. 34,35 The implementation of improved pharmacy services has been recognized as a means to effectively tackle issues pertaining to medications and drug-related concerns. The involvement of pharmacists in primary health care should be further elucidated in the management of patients with gout, particularly with regard to the current provision of patient education and the monitoring of medication adherence.…”

Section: Discussionmentioning

confidence: 99%

“…In addition to addressing bone‐related problems, rheumatologists are progressively inclined to engage in discussions pertaining to aspects beyond the direct pharmacological management of joint ailments, including patient quality of life and education 34,35 . The implementation of improved pharmacy services has been recognized as a means to effectively tackle issues pertaining to medications and drug‐related concerns.…”

Section: Discussionmentioning

confidence: 99%

Knowledge and attitudes of gout patients and their perspectives about diagnosis and management: A cross‐sectional study in Saudi Arabia

Khormi,

Basalem,

Al Muaddi

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

BackgroundGout is a chronic noncommunicable disease that might lead to multiple systemic complications if it is left untreated. The knowledge, attitudes, and perceptives among patients toward the diagnosis and management of gout are important indicators in determining the prognosis and predicting sequelae of the disease. This cross‐sectional survey aimed to assess the knowledge, attitudes, and perspectives of patients diagnosed with gout toward the disease diagnosis and treatment.MethodologyAn observational cross‐sectional study was conducted at university clinics and local health facilities in central Riyadh, Saudi Arabia, for the duration between April and August 2022. Pearson χ2 test was used to determine the difference in the proportion of patients who adapt different attitudes and perspectives in terms of their demographic variables. Statistical significance was defined as a p value less than .05.ResultsTwo‐hundred thirteen patients were involved in this study. The majority of the patients (84.0%) were diagnosed for more than 1 year. The majority of the patients (76.5%) were aged 25–60 years when they were diagnosed with gout. The most common complaint at the time of the diagnosis was joint pain (73.7%). The most commonly reported gout medication treatment being used was allopurinol accounting for 23.0%. The majority of the patients (83.6%) were satisfied regarding the effects of gout management on their job performance, work life, and careers. The vast majority (97.5%) reported that they are satisfied with the health service provided.ConclusionThe patients diagnosed with gout in Saudi Arabia exhibited a satisfactory level of information, attitude, and perspectives regarding their condition. The participants expressed a significant degree of satisfaction with the impact of gout management on their occupational performance, work‐life balance, and professional plans. Additional research is necessary to ascertain the risk factors associated with gout and provide suitable preventative interventions.

show abstract

“…Shared decision-making remains a topic ill studied in rheumatology, and tools to support physicians and patients in this process are lacking [ 4 ]. In a survey on gout treatment, rheumatologists indicated that no treatment choice was offered to the patient, and if patients could make choices, they often had difficulty making them [ 5 ]. The lack of patient knowledge on topics related to treatment options was perceived as a main barrier.…”

mentioning

confidence: 99%

The acknowledgment of the treatment burden in the disease burden

De Cock,

Dens,

Walker

et al. 2023

Rheumatology Advances in Practice

View full text Add to dashboard Cite

Shared decision-making in gout treatment: a national study of rheumatology provider opinion and practice

Cited by 6 publications

References 20 publications

Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients

Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients

Knowledge and attitudes of gout patients and their perspectives about diagnosis and management: A cross‐sectional study in Saudi Arabia

The acknowledgment of the treatment burden in the disease burden

Contact Info

Product

Resources

About